Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Teladoc Health reports on 3 months of 2023

4/27/23 TDOC

The Bank of America announced a quarterly dividend

4/26/23 BAC

The eBay announced a quarterly dividend

4/26/23 EBAY

The Pfizer announced a quarterly dividend

4/26/23 PFE

ZIL reported for 3 months of 2023 according to RAS

4/26/23 ZILL

SFI reported for 3 months of 2023 by RAS

4/26/23 SFIN

LSR reported for 3 months of 2023 according to RAS

4/26/23 LSRG

Activision Blizzard reported 3 months of 2023

4/26/23 ATVI

Abrau-Durso enters the energy drinks market

4/26/23 ABRD

Unipro will be managed by the head of Rosneft's Energy Department

4/26/23 UPRO